title: Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe.
authors.forename: Ralf R
authors.initials: RR
authors.lastname: Reinert
authors.forename: Peter
authors.initials: P
authors.lastname: Paradiso
authors.forename: Bernard
authors.initials: B
authors.lastname: Fritzell
mesh_terms: D002986:Clinical Trials as Topic; D017277:Drug Approval; D005060:Europe; D006801:Humans; D007115:Immunization Schedule; D011008:Pneumococcal Infections / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*
chemical_list: C538862:13-valent pneumococcal vaccine; D022242:Pneumococcal Vaccines